Becker Matthijs L, Kallewaard Marjon, Caspers Peter W J, Schalekamp Tom, Stricker Bruno H C
National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
Drug Saf. 2005;28(5):371-8. doi: 10.2165/00002018-200528050-00001.
Although the number of clinically relevant drug-drug interactions (DDIs) is probably low, DDIs may be responsible for a substantial number of hospital admissions. In some countries, the pharmacist is responsible for preventing the use of unsafe or non-effective drug regimens. Specifically they should avoid the dispensing of combinations of drugs that may cause serious DDIs. In order to assess the determinants related to community pharmacies and associated with these dispensings, a systematic literature review was conducted. Medline and International Pharmaceutical Abstracts were searched for articles published in English between 1993 and 2003. Additional relevant articles were identified by screening the reference lists of relevant articles. Seven papers were located. The determinants described in the literature were divided into three groups. The first group focussed on the relationship between the pharmacist and the prescriber. The number of prescribers is of importance as well as the number of dispensing pharmacies. Both a high number of primary care physicians and multiple dispensing pharmacies increased the risk of DDIs. The availability, quality and sensitivity of the medication surveillance software appeared to be a second important determinant. Both too many and too few signals increased the risk of dispensing interacting drugs. The third group of determinants was related to the pharmacist and pharmacy organisation. Signals from the surveillance program are usually judged first by technicians and subsequently managed by the pharmacist. Consequently, knowledge, instructions and supervision are important determinants. A fourth group of determinants was identified in literature assessing interventions by pharmacists, including interventions for DDIs. A higher workload was associated with lower intervention rates, which indicated a higher risk of dispensing interacting drugs. The determinants identified in this review can be used to develop strategies to minimise patient harm resulting from DDIs. Further assessment of the relation between these determinants and the dispensing of DDIs and of the relation between DDI-associated dispensing and patient harm is recommended.
虽然具有临床相关性的药物相互作用(DDIs)数量可能较少,但DDIs可能导致大量患者住院。在一些国家,药剂师负责防止使用不安全或无效的药物治疗方案。具体而言,他们应避免调配可能导致严重DDIs的药物组合。为了评估与社区药房相关并与这些调配行为有关的决定因素,进行了一项系统的文献综述。检索了Medline和《国际药学文摘》中1993年至2003年间以英文发表的文章。通过筛选相关文章的参考文献列表确定了其他相关文章。共找到七篇论文。文献中描述的决定因素分为三组。第一组关注药剂师与开处方者之间的关系。开处方者的数量以及配药药房的数量都很重要。初级保健医生数量多和多个配药药房都会增加发生DDIs的风险。药物监测软件的可用性、质量和敏感性似乎是第二个重要决定因素。信号过多和过少都会增加调配相互作用药物的风险。第三组决定因素与药剂师和药房组织有关。监测程序发出的信号通常首先由技术人员判断,随后由药剂师处理。因此,知识、指导和监督是重要的决定因素。在评估药剂师干预措施(包括针对DDIs的干预措施)的文献中确定了第四组决定因素。工作量越大,干预率越低,这表明调配相互作用药物的风险越高。本综述中确定的决定因素可用于制定策略,以尽量减少DDIs对患者造成的伤害。建议进一步评估这些决定因素与DDIs调配之间的关系,以及与DDIs相关的调配与患者伤害之间的关系。